The merger represents a near-total wipeout of existing BOLD equity value, with legacy stockholders retaining only ~3.8% of the combined entity. The pre-closing dividend of ~$44M-$48M provides some cash return but is dwarfed by the dilution. The key binary catalyst is the Beam litigation outcome, which could materially impair SERP-01's development path. Monitor the special meeting vote and Nasdaq listing decision for the combined company.
Price Chart
Executive Summary
Boundless Bio (BOLD) filed an S-4 registration statement for a reverse merger with privately-held Serapha Bio. The combined entity will focus on Serapha's SERP-01 base editing therapy for AATD, abandoning Boundless Bio's legacy oncology pipeline. Existing Boundless Bio stockholders are expected to own approximately 3.8% of the combined company on a fully-diluted basis, while Serapha securityholders (including ~$92M pre-closing financing investors) will own ~96.2%. Boundless Bio stockholders will receive a pre-closing dividend of ~$44M-$48M. The merger is subject to stockholder approval and Nasdaq listing.
Key Facts
- Existing BOLD stockholders will own ~3.8% of the combined company on a fully-diluted basis; Serapha securityholders will own ~96.2%.
- Boundless Bio stockholders will receive a pre-closing special cash dividend of approximately $44M-$48M.
- Serapha raised ~$138M in Series A financing and has commitments for ~$92M in pre-closing financing.
- The combined company will focus on Serapha's SERP-01 (in vivo base editing therapy for AATD) and will not continue Boundless Bio's legacy ecDNA oncology programs.
- Boundless Bio's legacy pipeline was discontinued after clinical failures (BBI-355, BBI-940, BBI-825).
- Serapha is a defendant in a trade secret misappropriation lawsuit filed by Beam Therapeutics (Beam) on September 25, 2026, relating to SERP-01.
- The exchange ratio is estimated at ~8.6737 shares of BOLD common stock per share of Serapha capital stock.
- Boundless Bio had 15 employees as of July 15, 2026 and net losses of $58.2M (FY2025) and $65.4M (FY2024).
- Serapha had an accumulated deficit of $170.1M as of June 30, 2026 (since inception in April 2026).
- The combined company will trade under the symbol AATD on Nasdaq, subject to approval.
Financial Impact
Existing BOLD stockholders face ~96.2% dilution, receiving a ~$44M-$48M pre-closing dividend. The combined company will have ~$230M in cash (Serapha's $138M Series A + $92M pre-closing financing) to fund SERP-01 development.
Risk Factors
- Beam Therapeutics trade secret lawsuit could delay or prevent SERP-01 development and commercialization.
- Nasdaq listing condition may not be satisfied, preventing the merger from closing.
- Combined company will need substantial additional capital beyond the ~$230M in cash to fund SERP-01 through regulatory approval and commercialization.
- SERP-01 is an early-stage, unproven base editing therapy with limited clinical data (4 patients in an IIT).
- If the merger fails, Boundless Bio may pursue liquidation, potentially returning little to no value to stockholders.
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4 Filing (Primary) | 0001193125-26-417903 |
| Document: d108148dex105.htm | 0001193125-26-417903 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 425 | — | awaiting T+20 | — | — |
Oct 8, 2026 17d ago | S-4 | $2.53 | awaiting T+20 | — | $2.38 (+5.93%) |
Aug 28, 2026 8w ago | 425 / 8-K | $2.81 $2.56 | ▼ −8.90% | ▼ −8.53% | $2.38 (−15.30%) |
Jul 8, 2026 15w ago | Insider Cluster | $2.51 $2.84 | ▲ +13.15% | ▲ +10.91% | $2.38 (−5.18%) |
Jul 6, 2026 15w ago | Insider Cluster | $2.50 $2.71 | ▲ +8.20% | ▲ +5.04% | $2.38 (−4.80%) |
Jun 29, 2026 16w ago | 3 | $2.50 $2.48 | ▼ −0.80% | ▲ +0.23% | $2.38 (−4.80%) |
May 8, 2026 24w ago | 8-K | $1.44 $1.42 | ▼ −1.39% | ▼ −1.41% | $2.38 (+65.28%) |
May 8, 2026 24w ago | Press Release | $1.44 $1.42 | ▲ +1.39% | ▲ +1.41% | $2.38 (−65.28%) |
Apr 17, 2026 27w ago | Press Release | $1.60 $1.42 | ▼ −11.25% | ▼ −15.45% | $2.38 (+48.75%) |
Apr 13, 2026 27w ago | 8-K | $1.56 $1.55 | ▲ +0.64% | ▲ +6.94% | $2.38 (−52.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers